0000000000374184

AUTHOR

Felix Momm

showing 3 related works from this author

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

2019

Abstract Introduction Quality of life (QoL) of comorbid patients with pulmonary malignancies is a key issue in considering fractionated stereotactic body radiotherapy (SBRT) indication. This study investigates the early impact of SBRT on QoL. Methods One hundred patients with pulmonary lesions were treated with SBRT from February 2011 to December 2014 within the prospective, monocenter, phase II STRIPE trial. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core module (EORTC QLQ-C30) and the QLQ-LC13 lung cancer-specific questionnaire were used to evaluate QoL before, 2 and 7 weeks after SBRT, then every 3 months for 2 years. We report on the ana…

Male0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyLung NeoplasmsHealth StatusRadiosurgeryEmotional function03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesAgedLungbusiness.industryCancerPrognosismedicine.diseasehumanitiesKarnofsky index030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCharlson comorbidity indexQuality of LifeFemaleDose Fractionation RadiationbusinessStereotactic body radiotherapyFollow-Up StudiesJournal of Thoracic Oncology
researchProduct

Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial.

2019

Preserving health related quality of life (HRQOL) plays an important role in considering stereotactic body fractionated radiotherapy (SBRT). The prospective monocenter phase II STRIPE trial investigated long-term HRQOL after SBRT, efficacy and toxicity.Patients with ≤2 pulmonary lesions ≤5 cm were treated with 4DPET/CT-based SBRT (3 × 12.5 Gy or risk-adapted 5 × 7 Gy, to 60% isodose). Follow up (FU) was performed 2 and 7 weeks after SBRT, then 3-monthly for 2 years with assessment of response (primary endpoint: 2-year cumulative incidence of local progression (LP); secondary endpoints: local progression free survival (LPFS), overall survival (OS) and toxicity (CTCAE)). Impact of predefined …

Oncologymedicine.medical_specialtyLung NeoplasmsFractionated radiotherapyRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineClinical endpointHumansRadiology Nuclear Medicine and imagingCumulative incidenceProgression-free survivalProspective StudiesLung cancerHealth related quality of lifebusiness.industryHematologymedicine.diseasehumanitiesRegimenOncology030220 oncology & carcinogenesisQuality of LifeDose Fractionation RadiationbusinessRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
researchProduct

Protective effect of amifostine on dental health after radiotherapy of the head and neck.

2000

Abstract Purpose: The cytoprotective agent amifostine has been shown to reduce the radiation-induced acute and chronic xerostomia in head and neck cancer patients. The purpose of this study was to evaluate whether or not amifostine also reduces the incidence of dental caries associated with the radiation-induced xerostomia. Methods and Materials: The dental status before and 1 year after radiotherapy was retrospectively compared in 35 unselected patients treated as part of the prospective randomized and multicenter open-label Phase III study (WR-38) at the University Hospitals of Heidelberg, Freiburg, and Erlangen. The WR-38 study compared radiotherapy in head and neck cancer with and witho…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentRadiation-Protective AgentsDental CariesXerostomiasymbols.namesakeAmifostinestomatognathic systemOral and maxillofacial pathologymedicineClinical endpointHumansRadiology Nuclear Medicine and imagingProspective StudiesRadiation InjuriesFisher's exact testAgedRetrospective StudiesRadiationbusiness.industryHead and neck cancerCase-control studyAmifostineMiddle Agedmedicine.diseaseSurgeryRadiation therapystomatognathic diseasesOncologyHead and Neck NeoplasmsConcomitantsymbolsFemalebusinessmedicine.drugInternational journal of radiation oncology, biology, physics
researchProduct